With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Nearly two years after he’d been treated for kidney cancer and felt like he was in the clear, Chuck Stravin received the news that some nodules in both of his lungs were growing at an aggressive pace.

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

Patients with kidney cancer who want more support during treatment can consider palliative care, whether it’s for symptoms or discussing goals and values. For patients with kidney cancer, ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

Built on Insights from Patients and Caregivers, the New Website Curates Trusted Resources from Leading Organizations in Kidney Cancer NUTLEY, N.J., Feb. 26, 2026 /PRNewswire/ -- Eisai Inc. announced ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

At Huntsman Cancer Institute, you receive expert, multidisciplinary care for kidney, or renal cell cancer through our Urologic Cancer Program. Your care team includes urologic oncologists, medical ...

A new report[i] released in line with Kidney Cancer Awareness Week by Kidney Cancer UK – the UK’s leading kidney cancer charity based in Guildford – has uncovered significant challenges facing kidney ...

The Kidney Cancer Association (KCA), a global community dedicated to serving and empowering patients and caregivers and ...

Kidney cancer is one of the 10 most-diagnosed cancers in the United States. Like many of the other cancers on that list—including colon and rectal cancer—kidney cancer is more common now than it used ...